MARKET

EARS

EARS

Auris Medical Holding Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8199
-0.0100
-1.21%
After Hours: 0.7617 -0.0582 -7.10% 16:42 03/27 EDT
OPEN
0.8550
PREV CLOSE
0.8299
HIGH
0.8550
LOW
0.7706
VOLUME
61.95K
TURNOVER
--
52 WEEK HIGH
7.00
52 WEEK LOW
0.6500
MARKET CAP
19.74M
P/E (TTM)
-0.1171
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EARS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EARS stock price target is 14.71 with a high estimate of 14.71 and a low estimate of 14.71.

EPS

EARS News

More
  • Auris Medical Holding Ltd. to Host Earnings Call
  • ACCESSWIRE · 3d ago
  • Auris Medical Holding Ltd. to Host Earnings Call
  • ACCESSWIRE · 03/19 11:00
  • The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review
  • Benzinga · 03/15 13:55
  • The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
  • Benzinga · 03/10 13:19

Industry

Biotechnology & Medical Research
-2.44%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About EARS

Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.
More

Webull offers kinds of Auris Medical Holding Ltd stock information, including NASDAQ:EARS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EARS stock news, and many more online research tools to help you make informed decisions.